Izazovi u tumačenju broja leukocita i nukleisanih eritrocita u hemolitičkoj bolesti novorođenčeta: prikaz slučaja o pouzdanosti rada hematološkog analizatora

Leukociti i nukleisani eritrociti u hemolitičkoj bolesti novorođenčeta

DOI: https://doi.org/10.5937/jomb0-60254

Sažetak


Predstavljen je slučaj hemolitičke bolesti novorođenčeta (HBN) izazvane majčinom aloimunizacijom na anti-E i anti-c antitela, što je dovelo do teške anemije, respiratorne insuficijencije i hiperbilirubinemije kod terminskog muškog novorođenčeta. Hematološka analiza izvršena pomoću automatizovanog analizatora Sysmex XN-3100 pokazala je lažno povišen broj leukocita od 163 × 10⁹/L, koji je kasnije manuelno korigovan na 28 × 10⁹/L zbog ekstremne interferencije nukleisanih eritrocita (više od 2.000 NRBC na 100 leukocita). Ovaj slučaj ilustruje analitička ograničenja savremenih hematoloških analizatora kod novorođenčadi sa izraženom eritroblastozom i naglašava suštinsku ulogu ručnog pregleda perifernog razmaza krvi i interdisciplinarne saradnje kliničara i laboratorije u obezbeđivanju dijagnostičke tačnosti.

 

Biografije autora

Marina Jakšić, Clinical center of Montenegro

Center for Science & Department of Laboratory Diagnostics, Institute for Children’s Diseases

Faculty of Medicine, University of Montenegro

doc. dr , Clinical Center of Montenegro

Department of Neonatology, Institute for Children’s Diseases

Faculty of Medicine, University of Montenegro 

doktor , Odjeljenje za radiološku dijagnostiku, Klinički centar Crne Gore

Department of Diagnostic Imaging

Objavljeno
2025/08/12
Broj časopisa
Ahead of print
Rubrika
Case Report

Sva prava zadržana (c) 2025 Marina Jakšić, Lidija Banjac , Boban Banjac

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.